Background: Immune checkpoint blockade against programmed death-ligand 1 (PD-L1) benefits only a subset of patients with esophageal squamous cell carcinoma (ESCC). The histone demethylase lysine-specific demethylase 5B (KDM5B) drives tumor growth, yet whether it also modulates anti-tumor immunity in ESCC is unknown. This study examined whether the microRNA-29c-3p (miR-29c-3p)/KDM5B axis influences KYSE150 cell behavior and immune-associated responses in vitro. Methods: We quantified KDM5B expression in ESCC cell lines and analyzed public datasets. KYSE150 cells were subjected to KDM5B knockdown or miR-29c-3p overexpression, followed by Cell Counting Kit-8, colony formation, Matrigel invasion, and wound healing. In direct-contact co-culture, tumor cells were exposed to activated peripheral blood mononuclear cells (PBMCs) together with anti-PD-L1; tumor-cell apoptosis, lactate dehydrogenase release, the CD8+ T-cell fraction, and interferon-γ (IFN-γ) output served as readouts. Direct targeting of KDM5B by miR-29c-3p was tested using a dual-luciferase assay coupled with rescue experiments. Results: Compared with normal esophageal epithelial cells, ESCC cells and tissues contained more KDM5B; in public cohorts, higher KDM5B was associated with poorer survival and reduced CD8+ T-cell infiltration. KDM5B silencing or miR-29c-3p overexpression reduced clonogenic growth (p < 0.001, p < 0.01), proliferative rate (p < 0.001, p < 0.001), Matrigel invasion (p < 0.001, p < 0.001), and wound closure (p < 0.01, p < 0.05), and upregulated PD-L1 (p < 0.001). Upon direct-contact co-culture with PBMCs, adding either KDM5B silencing or miR-29c-3p overexpression to anti-PD-L1 further enhanced tumor-cell apoptosis (p < 0.001, p < 0.001), lactate dehydrogenase release (p < 0.001, p < 0.001), the CD8+ T-cell proportion (p < 0.001, p < 0.001), and IFN-γ secretion (p < 0.001, p < 0.001). Importantly, these enhancements were partially attenuated, rather than completely reversed, when KDM5B was restored. A direct interaction between miR-29c-3p and the KDM5B 3′-untranslated region was demonstrated. Conclusions: Through direct targeting of KDM5B, miR-29c-3p restrains ESCC cell growth and remodels CD8- and IFN-γ-associated immune readouts in vitro. Exploiting the miR-29c-3p/KDM5B axis could help surmount resistance to PD-L1 blockade in ESCC, offering a mechanistic rationale for pairing epigenetic modulation with immunotherapy.